Your CRO Partner for
Preclinical Pharmacology
and In Vivo Services

Melior Discovery is a dedicated in vivo pharmacology CRO that strives to provide the highest quality service. We offer access to individual animal models and our theraTRACE® platform as contract research or on collaborative research basis. Our commitment to in vivo services since 2005 has made us a CRO of choice for hundreds of companies.

Efficacy Models

Indications Discovery

In Vivo Services

Expert Consulting

Specialized Animal Models

Drug Repositioning

Your CRO Partner For
In Vivo Pharmacology

Melior Discovery is a dedicated in vivo pharmacology CRO that strives to provide the highest quality service. We offer access to individual animal models and our theraTRACE® platform as contract research or on collaborative research basis. Our commitment to in vivo services since 2005 has made us a CRO of choice for hundreds of companies.

Melior Drug Discovery Philosophy

Watch the video

In Vivo Efficacy

Indications Discovery

Specialized Animal Models

Drug Repositioning

Andrew Reaume, PhD, CEO Melior Discovery



Trusted by the Top Leaders in Pharmacology

Melior Discovery's founding mission is drug repositioning - that is finding new uses for existing drugs.

State-of-the-art Preclinical Pharmacology Support

Melior provided state-of-the-art preclinical pharmacology support for a period of nearly a year, where a series of in vivo studies were completed on a weekly basis. The staff was extremely user-friendly and the operational processes were excellent. I can recommend Melior without reservation.

– Richard DiMarchi, PhD

Cox Professor of Chemistry & Gill Chair in Biomolecular Sciences
Indiana University, Department of Chemistry

State-of-the-art Preclinical Pharmacology Support

Melior provided state-of-the-art preclinical pharmacology support for a period of nearly a year, where a series of in vivo studies were completed on a weekly basis. The staff was extremely user-friendly and the operational processes were excellent. I can recommend Melior without reservation.

Richard DiMarchi, PhD

Cox Professor of Chemistry & Gil Chair in Biomolecular Sciences Indiana University, Department of Chemistry

Phenotypic screening uncovers otherwise
unpredicted new uses for a drug

Our in vivo pharmacology contract research capabilities

Phenotypic screening platform (theraTRACE® ) suited for drug repositioning

Learn about our in vivo services

contract research capabilities in most therapeutic areas.

Melior has pioneered a phenotypic

screening platform (theraTRACE® ) suited for in vivo services, drug repositioning, or for identifying novel indications from development-stage candidates.

Serving our community since 2005

8000

Thousands of studies

800

Hundreds of compounds evaluated

80

Dozens of animal models of human disease

Our Drug Discovery Philosophy

Increasingly, phenotypic screening is being recognized as the best strategy to uncover otherwise unpredicted new uses of therapeutics.

Recent Studies using Phenotypic Screening

Development of a novel secondary phenotypic screen to identify hits within the mycobacterial protein synthesis pipeline.
Burke C, Jankute M, Moynihan P, Gonzalez Del Rio R, Li X, Esquivias J, Lelièvre J, Cox JAG, Sacchettini J, Besra GS
Background: Whole-cell phenotypic screening is the driving force behind modern anti-tubercular drug discovery efforts. F...


An iPSC-Derived Neuron Model of CLN3 Disease Facilitates Small Molecule Phenotypic Screening.
Kinarivala N, Morsy A, Patel R, Carmona AV, Sajib MS, Raut S, Mikelis CM, Al-Ahmad A, Trippier PC
The neuronal ceroid lipofuscinoses (NCLs) are a family of rare lysosomal storage disorders. The most common form of NCL ...